Allurion shares surge 12.45% after-hours after reporting strong Q4 revenue growth and improved operating expenses.

Allurion Technologies surged 12.45% in after-hours trading following the announcement of preliminary Q4 2025 results showing revenue growth of 22% to 37% quarter-over-quarter, with full-year revenue reaching $15 million. The company highlighted significant improvements in operating expenses and operating losses, driven by its strategic pivot in 2025 and a refined commercial strategy. Management also emphasized potential FDA approval of the Allurion Smart Capsule as a catalyst for 2026, signaling optimism about future growth. The strong revenue performance and cost reductions aligned with the stock’s upward movement, reinforcing investor confidence in the firm’s operational turnaround and long-term prospects.